Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence

Zheng,Xi; Cui,Xiao-Xing; Gao,Zhi; Zhao,Yang; Shi,Yi; Huang,Mou-Tuan; Liu,Yue; Wagner,George  C.; Lin,Yong; Shih,Weichung   Joe; Rao,Chinthalapally  V.; Yang,Chung  S.; Conney,Allan  H.

doi:10.3892/etm.2011.203

Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence

Authors:
- Xi Zheng
- Xiao-Xing Cui
- Zhi Gao
- Yang Zhao
- Yi Shi
- Mou-Tuan Huang
- Yue Liu
- George C. Wagner
- Yong Lin
- Weichung Joe Shih
- Chinthalapally V. Rao
- Chung S. Yang
- Allan H. Conney
View Affiliations

Affiliations: Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA, Department of Psychology, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA, Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA, Chemoprevention Program, University of Oklahoma Cancer Institute, The University of Oklahoma, Oklahoma City, OK 73104, USA
Published online on: January 20, 2011 https://doi.org/10.3892/etm.2011.203
Pages: 221-228

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the inhibitory effect of dietary atorvastatin, dietary celecoxib and voluntary running wheel exercise (RW) alone or in combination on the formation and growth of androgen-independent LNCaP tumors in castrated severe combined immunodeficient (SCID) mice was determined. Male SCID mice were injected subcutaneously with androgen-dependent prostate cancer LNCaP cells. When the tumors reached a moderate size, the mice were surgically castrated and treated with atorvastatin (0.02% in the diet), celecoxib (0.05% in the diet) or RW alone or in combination for 42 days. RW or celecoxib alone had a moderate inhibitory effect on the androgen-independent growth of LNCaP tumors, while atorvastatin alone had little or no effect on tumor growth. Combinations of atorvastatin and celecoxib had a stronger inhibitory effect on the formation and growth of androgen-independent LNCaP tumors than either drug alone. A combination of RW together with atorvastatin and celecoxib had the most potent inhibitory effect on the progression of LNCaP tumors to androgen-independent growth. The serum concentration of atorvastatin after 2 weeks of oral administration of atorvastatin was 6.1 ng/ml. The serum concentration of celecoxib after treatment with dietary celecoxib for 2 weeks was 1,090 ng/ml. The serum concentration of atorvastatin, but not that of celecoxib, was significantly reduced when the two drugs were given in combination. The drug concentrations observed in the animal studies are comparable or less than those commonly found in humans treated with atorvastatin or celecoxib. The results indicate that the administration of atorvastatin and celecoxib together with voluntary exercise is an effective strategy for the prevention of prostate cancer progression from androgen dependence to androgen independence.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2.	Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL and Scher HI; American Society of Clinical Oncology: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 25:1596–1605. 2007. View Article : Google Scholar
4.	Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Zheng X, Cui XX, Gao Z, et al: Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res. 3:114–124. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, Kong AN, Paulino R, Shih WJ, Lin Y, Rabson AB, Reddy BS and Conney AH: Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res. 13:5480–5487. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ and Calle EE: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 16:2213–2217. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL and Freedland SJ: Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 116:3389–3398. 2010. View Article : Google Scholar
10.	Murtola T, Tammela TLJ, Lahtela J and Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 16:2226–2232. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Platz EA, Leitzmann MF, Visvanathan K, et al: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 98:1819–1825. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Bañez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ, Masko EM, Vollmer RT and Freedland SJ: Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 19:722–728. 2010.PubMed/NCBI
13.	Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G and Witte JS: COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 97:557–561. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Stock D, Groome PA and Siemens DR: Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am. 35:117–130. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Cerhan JR, Torner JC, Lynch CF, et al: Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control. 8:229–238. 1997.
16.	Wannamethee SG, Shaper AG and Walker M: Physical activity and risk of cancer in middle-aged men. Br J Cancer. 85:1311–1316. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ and Elliott FG: Case-control study of lifetime total physical activity and prostate cancer risk. Am J Epidemiol. 159:740–749. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ and Calle EE: Recreational physical activity and risk of prostate cancer in a large cohort of US men. Cancer Epidemiol Biomarkers Prev. 14:275–279. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Nilsen TI, Romundstad PR and Vatten LJ: Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer. 119:2943–2947. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Orsini N, Bellocco R, Bottai M, Pagano M, Andersson SO, Johansson JE, Giovannucci E and Wolk A: A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer. 101:1932–1938. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Antonelli JA, Jones LW, Bañez LL, Thomas JA, Anderson K, Taylor LA, Gerber L, Anderson T, Hoyo C, Grant D and Freedland SJ: Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol. 182:2226–2231. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ, Lin Y, Lu YP, Wagner GC and Conney AH: Inhibitory effect of voluntary running wheel exercise on the growth of human pancreatic Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice. Oncol Rep. 19:1583–1588. 2008.PubMed/NCBI
23.	Lindsey JK: Models for Repeated Measurments. Claredon Press; Oxford: 1993
24.	Zhang JY, Wang Y, Dudkowski C, Yang D, Chang M, Yuan J, Paulson SK and Breau AP: Characterization of metabolites of celecoxib in rabbits by liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 35:1259–1270. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Black AE, Hayes RN, Roth BD, Woo P and Woolf TF: Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos. 27:916–923. 1999.PubMed/NCBI
26.	Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC and Lameire NH: Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 18:967–976. 2003. View Article : Google Scholar : PubMed/NCBI
27.	Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L and Rao CV: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res. 66:4542–4546. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Reddy BS, Sugie S and Lowenfels A: Effect of voluntary exercise on azoxymethane-induced colon carcinogenesis in male F344 rats. Cancer Res. 48:7079–7081. 1988.PubMed/NCBI
29.	Cohen LA, Choi K, Backlund JY, Harris R and Wang CX: Modulation of N-nitrosomethylurea induced mammary tumorigenesis by dietary fat and voluntary exercise. In Vivo. 5:333–344. 1991.PubMed/NCBI
30.	Thompson HJ: Effects of physical activity and exercise on experimentally-induced mammary carcinogenesis. Breast Cancer Res Treat. 46:135–141. 1997. View Article : Google Scholar : PubMed/NCBI
31.	Michna L, Wagner GC, Lou YR, Xie JG, Peng QY, Lin Y, Carlson K, Shih WJ, Conney AH and Lu YP: Inhibitory effects of voluntary running wheel exercise on UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis. 27:2108–2115. 2006. View Article : Google Scholar : PubMed/NCBI
32.	Beavers KM, Brinkley TE and Nicklas BJ: Effect of exercise training on chronic inflammation. Clin Chim Acta. 411:785–793. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Mathur N and Pedersen BK: Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm. Jan. 11–2009.(E-pub ahead of print).
34.	Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ and Posvar EL: Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 60:687–695. 1996. View Article : Google Scholar : PubMed/NCBI
35.	Lennernas H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 42:1141–1160. 2003. View Article : Google Scholar : PubMed/NCBI
36.	Davies NM, McLachlan AJ, Day RO and Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 38:225–242. 2000. View Article : Google Scholar : PubMed/NCBI